SB 964 adds mirrored provisions to the Health and Safety Code and the Insurance Code that let an enrollee’s or insured’s treating provider request — and require plans and insurers to grant — authority to adjust a drug’s dose or frequency without prior authorization when certain conditions are met. The bill covers drugs used for chronic conditions and cancer treatment, excludes opioids and scheduled controlled substances, and limits dose adjustments without prior authorization to two times.
The bill matters because it narrows the reach of utilization review for routine, clinically driven dose changes and bars plans from limiting or excluding coverage when a patient has been continuously using a prescription selected by their prescriber while covered by current or previous insurance. That shift reduces a common administrative barrier for prescribers and patients, but it raises implementation, cost‑containment, and enforcement questions for plans, regulators, and pharmacies.
At a Glance
What It Does
SB 964 creates Section 1367.225 in the Health and Safety Code and Section 10123.1934 in the Insurance Code that eliminate prior‑authorization and subsequent utilization management for treating‑provider requested dose or frequency adjustments when the drug was previously approved for the patient’s chronic condition or cancer treatment, the prescriber continues to prescribe it, the drug is not an opioid or scheduled controlled substance, and the dose hasn’t been adjusted more than twice without prior authorization.
Who It Affects
Commercial health care service plans regulated by the DMHC and regulated health insurers are directly affected, along with treating providers, pharmacies, and patients on chronic medications or receiving cancer treatment; Medi‑Cal managed care plans are explicitly carved out. Self‑funded ERISA plans are not addressed and may remain outside the state law’s reach.
Why It Matters
By removing a common prior‑authorization barrier for routine dose changes, the bill changes how clinical discretion and utilization management interact in California, potentially speeding patient access but also shifting clinical, financial, and operational risk onto plans, regulators, and pharmacies. It also introduces criminal exposure for willful Knox‑Keene violations, complicating enforcement.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB 964 directs both state‑regulated health care service plans and regulated health insurers to accept dose or frequency adjustments requested by a patient’s treating provider without requiring prior authorization or subjecting the change to subsequent utilization management — but only if a handful of conditions are met. The provider must be continuing to prescribe the same drug that was previously approved by the plan or insurer for the patient’s chronic condition or cancer treatment.
The drug must not be an opioid or other scheduled controlled substance. The statutory text also caps the number of times a prescriber may make such adjustments without triggering prior authorization: no more than two adjustments.
The bill creates parallel provisions in the Health and Safety Code (section 1367.225) and the Insurance Code (section 10123.1934), so both DMHC‑regulated plans and DOI‑regulated insurers follow substantially the same rule. SB 964 adds a separate protection that bars a plan or insurer from limiting or excluding coverage for a prescription if the insured or enrollee has been continuously using that drug for the condition while covered by their current or prior health coverage.
That language is aimed at preventing formularies or coverage rules from disrupting treatment when patients move between carriers.SB 964 expressly exempts Medi‑Cal managed care plans from the Health and Safety Code provision. The bill does not amend federal ERISA law and therefore does not explicitly reach self‑funded employer plans; the practical effect for those plans will depend on ERISA preemption analysis.
Enforcement will follow existing regulatory authorities: DMHC oversight for Knox‑Keene plans and DOI enforcement for insurers. The bill’s legislative digest notes that a willful violation of Knox‑Keene provisions is a crime, which triggers a state‑mandated local program declaration in the fiscal language.
The Five Things You Need to Know
The bill prohibits prior authorization and subsequent utilization management for treating‑provider requested dose or frequency adjustments, provided the drug was previously approved by the plan or insurer for the enrollee’s or insured’s chronic condition or cancer treatment.
SB 964 excludes opioids and other scheduled controlled substances from the prior‑authorization exemption — those drugs remain subject to existing controls.
A treating provider can make no more than two dose adjustments without prior authorization; any further adjustments require prior authorization.
If a patient has been continuously using a prescribed drug while covered by current or previous health coverage, the plan or insurer may not limit or exclude coverage of that prescription.
The Health & Safety Code provision (for Knox‑Keene plans) explicitly does not apply to Medi‑Cal managed care plans; the bill creates parallel Insurance Code language for regulated insurers.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Allow treating providers to adjust dosing without prior authorization for DMHC‑regulated plans
This section requires health care service plans regulated under Knox‑Keene to grant a treating provider authority to change dose or frequency without prior authorization when the drug was previously approved by the plan for the enrollee’s chronic condition or cancer treatment, the provider continues to prescribe it, the drug is not an opioid or scheduled controlled substance, and dose adjustments have not exceeded two instances. It also prohibits the plan from limiting or excluding coverage when the enrollee has been continuously using the drug while covered by current or previous coverage. The clause carving out Medi‑Cal managed care plans narrows the statute to commercial and other DMHC‑regulated lines. Practically, DMHC‑regulated plans will need to update PA policies, claims workflows, and provider communications to implement this rule.
Mirror obligation for DOI‑regulated insurers
This section imposes the same prior‑authorization and coverage protections on health insurers regulated by the California Department of Insurance. Insurers must permit treating providers to change dose or frequency without prior authorization under the same conditions and must not limit coverage when the insured has continuous prior use. Insurers will need to adapt medical policy, utilization management protocols, and adjudication rules; the section creates parity between DMHC and DOI regimes for the covered populations.
No state reimbursement required; criminal‑penalty fiscal rationale
The bill’s fiscal language states the act imposes a state‑mandated local program only because it creates or modifies a crime or infraction, and therefore no state reimbursement is required under Article XIII B of the California Constitution. This mirrors the underlying enforcement architecture: willful Knox‑Keene violations can be crimes. The practical effect is that local agencies aren’t allocated separate reimbursement, but regulators and plan compliance teams shoulder enforcement and implementation responsibilities.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients with chronic conditions and people undergoing cancer treatment — they face fewer interruptions when a prescriber makes routine dose or frequency changes, and they gain protection from coverage exclusion when they’ve been continuously using the same prescription across plans.
- Treating providers (physicians, nurse practitioners, physician assistants) — they get clearer authority for clinical dose adjustments without waiting for prior authorization, reducing administrative friction and potential delays in care.
- Pharmacies and pharmacists — fewer point‑of‑sale prior‑authorization denials for incremental dose changes should reduce time spent on PA requests and appeals, speeding dispensing for routine adjustments.
Who Bears the Cost
- Health plans and regulated insurers — they must revise utilization management protocols, update claims and adjudication systems, and may face higher drug spend or more off‑label dosing variability because routine dose adjustments won’t be subjected to prior‑authorization screening.
- State regulators (DMHC and Department of Insurance) — they will need to monitor compliance, interpret ambiguous statutory language, and potentially investigate willful violations without additional reimbursement for those enhanced responsibilities.
- Employers with self‑funded ERISA plans and third‑party administrators — while ERISA plans are not explicitly covered, the bill may create market pressures or administrative friction if carriers and vendors standardize workflows across insured and self‑funded products.
Key Issues
The Core Tension
The core tension is between clinician autonomy and continuity of care on one side, and a payer’s role in safety oversight and cost control on the other: SB 964 prioritizes prescriber discretion for routine dose changes to avoid treatment delays, but in doing so it removes a key utilization‑management lever that plans use to ensure safety, appropriate dosing, and cost containment — and it leaves major implementation and fraud‑control questions unresolved.
SB 964 resolves a familiar access problem — prior authorization delays for routine dose changes — by stripping away utilization review in a narrow set of circumstances. That simplicity brings several implementation gaps.
The statute does not define what it means for a treating provider to be "granted the authority" operationally: must plans change internal medical‑policy documents, accept a prescriber’s electronic order at face value, or create a new attestation workflow? Claims systems, pharmacy benefit managers, and point‑of‑sale adjudication engines will need explicit implementation rules to avoid confusion and claim denials.
Proof standards and fraud controls are another unresolved area. The bill bars plan exclusions when a patient has been "continuously using" a drug under current or previous coverage, but it does not set an evidentiary standard for continuous use (prescription fill history, prescriber attestation, medical records).
That gap could produce disputes, retrospective denials, or incentives to game the standard. The two‑adjustment cap is administratively simple but clinically blunt: some conditions require serial titrations over time and the statute offers no clinical exceptions or expedited authorization pathway beyond the binary two‑adjustment rule.
Finally, the statutory criminal exposure for willful Knox‑Keene violations raises the stakes of compliance but may chill aggressive regulatory solutions and invite litigation over intent and enforcement authority.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.